Sorrento Therapeutics Inc. announced that it has acquired the exclusive rights to Cynviloq in Australia, Canada and Mexico from Samyang Biopharmaceuticals, a South Korean corporation. Sorrento has the exclusive rights to Samyang's Cynviloq (marketed as Genexol-PM in South Korea and other countries) in the US and the 27 countries of the EU. According to the company, Cynviloq (IG-001; a paclitaxel-loaded micellar diblock copolymer) is a next-generation branded paclitaxel formulation for the potential treatment of metastatic breast cancer, non-small cell lung cancer, pancreatic cancer and other solid tumors.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
67,200 KRW | -1.18% | -2.47% | -2.61% |
1st Jan change | Capi. | |
---|---|---|
-2.61% | 375M | |
-4.26% | 264B | |
-8.17% | 88.75B | |
-0.22% | 44.48B | |
-0.24% | 39.31B | |
+5.17% | 38.3B | |
-2.14% | 37.43B | |
-16.34% | 30.24B | |
-4.23% | 29.35B | |
+1.14% | 22.03B |
- Stock Market
- Equities
- A000070 Stock
- News Samyang Holdings Corporation
- Sorrento Therapeutics Acquires the Exclusive Rights to Cynviloq to Expand into Australia, Canada and Mexico